Drug developer Aristea Therapeutics rakes in $15 mln Series A
San Diego-based Aristea Therapeutics, a drug developer, has secured $15 million in Series A funding. The investor was Novo Holdings A/S. In connection with the financing, Dr. Tiba Aynechi and Dr. Ken Harrison from Novo Ventures (US) have been named to Aristea's board of directors.
18 December 2018•1 min read
